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ABSTRACT
Objective: To investigate the efficacy of levonorgestrel-releasing intra-uterine system 
(LNG-IUS) treatment in patients affected by atypical complex hyperplasia/endometrial 
cancer (ACH/EC) wishing to preserve their fertility and to present fertility outcomes of those 
patients who actively tried to conceive.
Methods: Data of consecutive women with ACH/EC who underwent fertility-sparing 
treatment using LNG-IUS were retrospectively evaluated.
Results: Overall, 48 patients and the mean (±standard deviation) length of follow-up was 
82.6±47.2 months. Among patients with ACH, 25/28 (89.3%) had a complete response (CR), 
2/28 (7.1%) had a partial response (PR) and 1/28 (3.6%) had a progressive disease (PD). 
Mean (±standard deviation) time to CR was 6.7±4.0 months. Among patients with G1 EC, 
13/16 (81.3%) had a CR, 1/16 (6.3%) had a PR and 2/16 (12.5%) had a PD. Mean (±standard 
deviation) time to CR was 5.0±2.9 months. Among patients with G2 EC, 3/4 (75.0%) had a 
CR and 1/4 (25.0%) had a PD. Mean (±standard deviation) time to CR was 4.0±0 months. 
Only 19 (39.6%) patients who had CR actually attempted to conceive. Eleven (57.9%) women 
tried to conceive naturally while 8 (42.1%) women underwent an in vitro fertilization (IVF). 
Fourteen (73.7%) patients wishing to conceive achieved a pregnancy (6 spontaneously and 8 
through IVF).
Conclusions: Fertility-sparing treatment of patient with ACH/EC with LNG-IUS achieves high 
regression rates and good fertility outcomes. Future larger multi-institutional studies should 
be designed to confirm these preliminary findings.
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INTRODUCTION
Endometrial hyperplasia (EH) is the precursor of endometrial cancer (EC) [1]. When no 
treatment is performed, the risk of progression from EH to carcinoma is 1% for patients with 
simple hyperplasia, 3% for patients with non-atypical complex hyperplasia (non-ACH) and 
15%–75% for patients with atypical complex hyperplasia (ACH) [2]. Invasive EC can already 
be found in approximately 30%–43% of patients initially diagnosed with ACH [3,4].
Worldwide in 2012, 527,600 women were diagnosed with EC, which is currently the most 
common malignancy of the female genital tract in developed countries [5]. In 2017, according 
to the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, 
the USA estimated number of new cases of EC was 61,380 women while the estimated number 
of deaths was 10,920 women [6]. Although it is mainly a disease affecting postmenopausal 
women, 25% of them are premenopausal and 3%–5% are under the age of 40 years [7].
The current standard treatment of ACH and EC is hysterectomy with bilateral salpingo-
oophorectomy and with or without peritoneal and retroperitoneal staging [8-10]. Although 
this approach offers a good 5-year oncologic survival outcome of 75%–90% in the overall 
population [11], it prevents prospects of future fertility. Furthermore, surgical treatment may 
be associated with intra- and postoperative complications, particularly in those populations 
of patients who are more frequently affected by ACH/EC such as obese women and 
conservative options may be chosen in this [12,13].
Given this background, the standard surgical option of hysterectomy and bilateral salpingo-
oophorectomy may not be ideal for women interested in future fertility. Thus, conservative 
strategies should be discussed with patients affected by ACH/EC along with the associated 
outcomes of each approach. Different fertility-sparing options have been demonstrated safe 
and feasible such as oral hormonal therapy, hysteroscopic resection of focal lesions, and the 
use of medicated intra-uterine systems [14].
The primary outcome of the current study was to investigate the efficacy of the treatment 
with levonorgestrel-releasing intra-uterine system (LNG-IUS) in patients affected by ACH/
EC who wish to preserve their fertility. Secondary outcomes of this study are to present the 
fertility outcomes of those patients who actively tried to conceive after the treatment.
MATERIALS AND METHODS
A large institutional prospectively collected database including patients between 2004 and 
2017 was retrospectively reviewed, searching records of women with ACH/EC who underwent 
fertility-sparing treatment using LNG-IUS. All patients gave consent for the use of personal 
information for health research. The Institutional Review Board (IRB) of “Fondazione IRCCS 
Istituto Nazionale dei Tumori”– Milan approved the collection and use of patients' clinical 
data for this retrospective study (IRB approval number: INT/MI/006812).
Inclusion criteria were: fertile age, histologically proven ACH or well-differentiated (G1)/
moderately-differentiated (G2) endometrioid EC, tumor that was presumed International 
Federation of Gynecology and Obstetrics (FIGO) stage IA limited to the endometrium at 
transvaginal ultrasound, desire to preserve their fertility.
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Exclusion criteria were: incomplete medical records, age <18 years old, evidence of 
myometrial/cervical invasion, retroperitoneal lymph node involvement, suspicion of 
synchronous ovarian tumors at diagnosis, and/or distant metastasis at imaging assessment, 
women unwilling to undergo regular follow-up, use of additional systemic progesterone 
agents to treat ACH/EC during or after LNG-IUS placement. any condition precluding the 
acquisition of the informed written consent.
The primary outcome of this study was to estimate the proportion of women with ACH/EC 
showing histological regression after treatment with the LNG-IUS. The secondary outcome was to 
present the fertility outcomes of women wishing to conceive after that regression was achieved.
All patients were evaluated at baseline by pelvic examination, transvaginal ultrasound and 
abdominal magnetic resonance imaging (MRI). All imaging techniques were performed 
by expert physician specifically trained in gynecologic oncology. In particular, all 
ultrasonographic scans were performed by the same operator (Valentina Chiappa). In all 
the cases, the histologic diagnosis was performed by hysteroscopy; two expert pathologists 
specialized in gynecologic oncology examined all the slides and they always evaluate all the 
subsequent pathology slides from treatment and surveillance.
Once the diagnosis of ACH or EC was posed, all patients were thoroughly counseled on the 
merits, disadvantages, and risks of surgical and LNG-IUS treatments. Women accepting to 
receive conservative treatment were inserted an IUS releasing 20 µg of LNG daily (Mirena®; 
Bayer Schering Pharma AG, Berlin, Germany). Response to treatment was evaluated at 
endometrial biopsies obtained by hysteroscopy and classified as follows: complete response 
(CR) was defined as the lack of residual ACH or EC, partial response (PR) was defined if 
histological downgrade was diagnosed during follow-up, stable disease (SD) was defined 
as no evidence of disease regression/progression, progressive disease (PD) was defined if 
histological upgrade was diagnosed during follow-up. Time to CR was measured from the 
LNG-IUS insertion. Recurrence was defined as the presence of ACH or EC during follow-up 
after an endometrial sample that showed CR. Time to recurrence was measured since the 
date of CR.
At follow-up all patients were evaluated by hysteroscopy. LNG-IUS was left inside the uterus 
and 5 endometrial biopsies were always performed (at anterior, posterior, right, left uterine 
walls and fundus). In addition, all patients were assessed by abdominal MRI every 6 months 
to evaluate disease status. First follow-up was performed at 3 months and 6 months, then 
every 6 months until the end of treatment or until recurrence. Patients with PR or SD at 3- 
and 6-month follow-up continued LNG-IUS treatment until 9-month follow-up and then they 
were invited to undergo surgery, while those with PD were immediately proposed to undergo 
surgery. On the basis of ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer 
recommendation [15], women with CR who wanted to become pregnant, were removed 
LNG-IUS and were encouraged to conceive immediately or referred to in vitro fertilization 
(IVF) according to the clinical/gynecological history of themselves and of their partners. 
Women trying to conceive both naturally or by IVF were assessed through hysteroscopy every 
3 months until they achieve pregnancy or decided to stop trying to conceive.
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RESULTS
A total of 48 patients were included in the current study and complete data on their follow-up 
were available. The main characteristics of the study population are reported in Tables 1 and 2. 
The mean (±standard deviation) age of the patients included in the study was 34.5 (±5.0) years 
and a total of 10/48 (20.8%) women had previous live births.
The mean (±standard deviation) length of follow-up of the whole study population was 
82.6±47.2 months. Overall, after conservative treatment with LNG-IUS, a total of 41/48 
(85.4%) patients had a CR, 3/48 (6.3%) patients had a PR, 0/48 (0%) had a SD, and 4/48 
(6.3%) had a PD. Mean (±standard deviation) time to CR was 7.6±4.0 months. Seventeen 
(41.5%) out of 41 women had a recurrence that occurred in 6/41 (14.6%) cases under LNG-
IUS treatment (4 ACH and 2 EC grade 1). Mean (±standard deviation) time to recurrence 
in the study population was 28.6±20.1 months. Details about response to conservative 
treatment according to histological diagnosis at baseline are shown in Table 3. Noteworthy, 
3/48 (6.3%) women, all with G1 EC, had a synchronous ovarian cancer.
Among those 41 women who achieved a CR, only 19 (39.6%) patients actually attempted 
to conceive. Eleven (57.9%) women tried to conceive naturally while 8 (42.1%) women 
underwent an IVF. Fourteen (73.7%) out of 19 patients wishing to conceive achieved a 
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Menarche age (yr) 12.5±1.6
Live births 0 (0–2)
Previous hormonal contraceptive 25 (52.1)
Previous IVF 5 (10.4)
Data are presented as mean±standard deviation, median (range), or number (%).
BMI, body mass index; IVF, in vitro fertilization.
Table 2. Main characteristics of the study population according to the disease






Smokers Diabetes PCOS Synchronous 
ovarian cancer
HNPCC
ACH 28/48 (58.3) 35.1±5.3 25.0±4.3 7/28 (25.0) 1/28 (3.6) 3/28 (10.7) 0/28 (0) 0/28 (0)
EC G1 16/48 (33.4) 33.4±5.0 22.8±4.6 5/16 (31.3) 1/16 (6.3) 2/16 (12.5) 3/16 (18.8) 2/16 (12.5)
EC G2 4/48 (8.3) 34.5±3.3 31.3±14.5 3/4 (75) 0/4 (0) 3/4 (75.0) 0/4 (0) 0/4 (0)
Total 48 (100) 34.5±5.0 24.9±6.1 15/48 (31.3) 2/48 (4.2) 8/48 (16.7) 3/48 (6.3) 2/48 (4.2)
Data are presented as mean±standard deviation or number (%).
ACH, atypical complex hyperplasia; BMI, body mass index; EC, endometrial cancer; G, grade; HNPCC, hereditary non-polyposis colorectal cancer; PCOS, 
polycystic ovary syndrome.
Table 3. Therapeutic efficacy outcomes
Characteristics CR PR PD Time to CR  
(mo)




ACH 25/28 (89.3) 2/28 (7.1) 1/28 (3.6) 6.7±4.0 9/25 (36.0) 34.0±22.4 76.4±48.8
EC G1 13/16 (81.3) 1/16 (6.3) 2/16 (12.5) 5.0±2.9 5/13 (38.5) 25.0±12.9 85.3±48.3
EC G2 3/4 (75.0) 0/4 (0) 1/4 (25.0) 4.0±0 3/3 (100) 14.3±1.5 115.5±2.6
Total 41/48 (85.4) 3/48 (6.3) 4/48 (8.3) 7.6±4.0 17/41 (41.5) 28.6±20.1 82.6±47.2
Data are presented as mean±standard deviation or number (%).
ACH, atypical complex hyperplasia; CR, complete response; EC, endometrial cancer; G, grade; PD, progressive disease; PR, partial response.
pregnancy (6 spontaneously and 8 through IVF); among these patients 11/14 (78.6%) had a 
single pregnancy, whereas 3/14 (21.4%) women had a twin pregnancy. One (7.1%) pregnancy 
terminated in late miscarriage at the 20th week, one (7.1%) intrauterine fetal death at 37th 
week was reported, while 11 (78.7%) women delivered at full term and one woman (7.1%) 
delivered beyond at late term. Spontaneous delivery occurred in 9/12 (75.0%) patients 
while caesarean section was performed in 3/12 (25.0%) cases. Table 4 summarizes detailed 
information on fertility outcomes in the study population.
All patients with PD and recurrence received conventional surgery.
DISCUSSION
This study investigated the efficacy and fertility outcomes of the treatment with LNG-IUS 
in patients of reproductive age affected by ACH/EC, reporting three main messages. Firstly, 
the conservative strategy with LNG-IUS was demonstrated efficacious in 41/48 (85.4%) 
patients. Secondly, 17/41 (41.5%) women had a recurrence and, in most of the cases (11/17, 
64.7%), recurrence was reported among women who removed the LNG-IUS. Thirdly, in our 
study population, about 40% of the patients who achieved a CR attempted to conceive and 
pregnancy occurred in the majority of the cases (14/19, 73.7%).
The relationship between epidemiological risk factors and the progression to EC can be 
explained by the unopposed estrogen hypothesis [16]. Progesterone, by antagonizing the 
effect of estrogen on the endometrium, may reverse this neoplastic process. In particular, 
treatment with progesterone/progestin works as in inhibition of the estrogen receptor, 
leading to a decrease in endometrial cell mitosis, promotion of apoptosis, and production 
of secretory endometrium. The use of progesterone/progestins in human EH and cancer has 
been described since the sixties [17-20]. Available evidence showed a variable range of risks 
for persistence or progression of EH in women treated with progestin, 1% for patients with 
simple hyperplasia, 3% for patients with non-ACH and 15%–75% for patients with ACH [2]. 
Both oral and local progestins have been investigated for conservative treatment of patients 
with ACH/EC [21,22]. In the current study, all women were treated with the same progestin 
treatment using the LNG-IUS. In 2012, a systematic review and meta-analysis was performed 
to compare the therapeutic efficacy of LNG-IUS with oral progestins for treatment of patients 
with ACH or early EC. The Authors concluded that there was a lack of high quality evidence 
for the efficacy of progestin in ACH or EC. However, available evidence suggested that 
treatment with oral or intrauterine progestin were similarly effective. Furthermore, it was 
pointed out that the risk of progression during treatment was small but longer follow-up was 
required [22]. In 2013, an English comparative cohort study addressed the issue of long-term 
efficacy in patients with EH and ACH; this study included women with complex non-atypical 
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ACH 11/28 (39.3) 6/11 (54.5) 2/11 (18.2) 5/6 (83.3) 1/6 (16.7) 5/28 (17.9) 4/6 (66.6) 1/6 (16.7) 1/6 (16.7) 0/6 (0)
EC G1 8/16 (50.0) 8/8 (100) 6/8 (75.0) 6/8 (75.0) 2/8 (25.0) 7/16 (43.8) 5/8 (62.5) 2/8 (25.0) 0/8 (0) 1/8 (12.5)
EC G2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Total 19/44 (43.1) 14/19 (73.7) 8/19 (41.2) 11/14 (78.6) 3/14 (21.4) 12/44 (27.3) 9/14 (64.3) 3/14 (21.5) 1/14 (7.1) 1/14 (7.1)
Data are presented as number (%).
ACH, atypical complex hyperplasia; ART, assisted reproductive techniques; EC, endometrial cancer; G, grade.
hyperplasia or ACH who were treated with the LNG-IUS (n=250) or oral progestogens 
(n=94). The mean (±standard deviation) length of follow-up in the two groups was 66.9±35.1 
months for the LNG-IUS and 87.2±45.5 months for the oral progestin group. Regression of 
hyperplasia was achieved in 94.8% (237/250) of patients with the LNG-IUS compared with 
84.0% (79/94) of patients treated with oral progestogens (p=0.001). Regression rate was 
significantly higher for complex non-atypical hyperplasia in patients with LNG-IUS (221/229, 
96.5%) versus those with oral progestogens (73/81, 90.1%; p=0.032). However, no difference 
was reported between the two treatment groups since regression of ACH was reported in 
76.2% (16/21) of patients with the LNG-IUS compared with 46.2% (6/13) of patients treated 
with oral progestogens (p=0.082) [23]. Only scanty evidence is available on the use of only 
LNG-IUS in patients with EC and no direct comparison with oral progestins have been 
performed [22,24]. Montz and colleagues [24] reported data on the use of local progestins 
in patients with EC. They conducted a study to assess the feasibility of using a progesterone-
containing intrauterine device to treat presumed FIGO stage IA, grade 1 endometrioid cancer 
in women at high risk for perioperative complications (American Society of Anesthesiologists 
class III or IV). Out of sixteen eligible patients, 12 women with a mean (±standard deviation) 
age of 60±16 years, were finally included in the study. Histologic studies identified no residual 
carcinoma in 6/12 (50%) women at 3 months, 7/11 (63.6%) women at 6 months, 7/9 (77.8%) 
women at 9 months, and 6/8 (75.0%) women at 12 months. Recently, Pal et al. [25] conducted 
a study to assess the efficacy of the LNG-IUS for treatment of 46 patients ACH or low-grade 
EC. At 6-month follow-up, out of 32 evaluable patients, 15 (47%) had ACH, 9 (28%) had G1 
EC (28%), and 8 (25%) had grade 2 EC. Overall response rate was 75% (95% confidence 
interval [CI]=57–89) at 6 months; 80% (95% CI=52–96) in ACH, 67% (95% CI=30–93) in 
grade 1 EC, and 75% (95% CI=35–97) in grade 2 EC. However, among patients with G1 EC 
only 22.2% achieved CR at 6-month follow-up versus the CR rate of 81.3% reported in our 
study. It should be underlined that patients included in the two studies are completely 
different. In our study only fertile patients were included and the mean (±standard deviation) 
body mass index (BMI) was 24.9±6.1. In the study by Pal et al. [25] a mixed population of 
fertile and postmenopausal women were included with a significantly higher median (range) 
BMI of 45.45 (19–74). Thus, it cannot be excluded that these baseline characteristics may have 
influenced response to treatment.
Some important issues about conservative treatment of patients with ACH/EC wishing to 
conceive should be addressed. A first critical issue in endometrial tissue studies is diagnostic 
reproducibility. The lack of standardized pathology review by pathologists in most studies 
may contribute to the observed variability in outcomes. For this reason, we deem that, when 
conservative treatment is chosen for patients with ACH/EC, it is recommendable that follow-
up consultations are performed in the same institution and that specimens are examined by 
an expert pathologists in gynaecologic diseases to increase histological assessment (ACH 
or EC) and the reliability of tumor grading [15]. Secondly, robust evidence on the optimal 
dosage of progestins and, in particular, on the best formulation (oral versus local) is still 
almost completely lacking and the regimens advocated are essentially arbitrary [26]. In 
our opinion, the use of LNG-IUS may represent an excellent choice for the conservative 
management of ACH/EC due to its good safety and tolerability profile [27,28]. A third relevant 
point is the potential coexistence of other tumors, in particular of ovarian cancer. In our 
study population, three (6.3%) women with EC G1 had a synchronous ovarian cancer. This 
result is in line with the prevalence reported in previous publications that is between 5% and 
6.5% [29,30]. For this reason, when the fertility sparing management is adopted it may be 
recommendable to perform regularly a transvaginal ultrasound evaluation during the follow-
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up of the patient. A fourth point that deserves attention is the limited number of patients 
that actually attempted to conceive. Thus, clinicians should thoroughly inform the patients 
on which is the standard management (hysterectomy and bilateral salpingo-oophorectomy) 
of ACH/EC and on the potential risks of a fertility-sparing treatment. Furthermore, patients 
should be clearly informed that the use of a conservative treatment only aims to create a time 
window to allow achieving a pregnancy and should not be considered as a long-term solution 
for their disease.
The current study is mainly limited by the inherent biases of the retrospective study design. 
In addition, the findings of this study should be considered carefully, because high response 
rates may be related to careful selection of patients for conservative therapy. However, 
although the overall number of participants reported in this study was small, this report is 
the largest case series investigating the efficacy and fertility outcomes of the treatment with 
LNG-IUS in patients of reproductive age affected by ACH/EC. In addition, it reports 4 cases 
of patients affected by EC G2 treated conservatively, showing a very promising rate of CR 
(75%). However, it should be pointed out that all these 3 patients relapsed in about 14 months 
and, despite our strong recommendations, they did not attempt to conceive. Therefore, 
these preliminary data suggests the possibility of a fertility-sparing option in patients with 
EC G2, opening the way for applying this treatment modality in a larger number of fertile 
women. However, these findings should be confirmed in larger population of patients to be 
considered reliable.
In conclusion, fertility-sparing treatment of patient with ACH/EC with LNG-IUS achieves 
high regression rates and good fertility outcomes. Future larger multi-institutional studies 
should be designed to confirm these preliminary findings and to draw any definitive 
conclusion on this issue.
REFERENCES
 1. Bray F, Dos Santos Silva I, Moller H, Weiderpass E. Endometrial cancer incidence trends in Europe: 
underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev 2005;14:1132-42. 
PUBMED | CROSSREF
 2. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of 
“untreated” hyperplasia in 170 patients. Cancer 1985;56:403-12. 
PUBMED | CROSSREF
 3. Leitao MM Jr, Han G, Lee LX, Abu-Rustum NR, Brown CL, Chi DS, et al. Complex atypical hyperplasia 
of the uterus: characteristics and prediction of underlying carcinoma risk. Am J Obstet Gynecol 
2010;203:349.e1-6. 
PUBMED | CROSSREF
 4. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, et al. Concurrent endometrial 
carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic 
Oncology Group study. Cancer 2006;106:812-9. 
PUBMED | CROSSREF
 5. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J 
Clin 2015;65:87-108. 
PUBMED | CROSSREF
 6. National Cancer Institute. Cancer stat facts: uterine cancer [Internet]. Bethesda, MD: National Cancer 
Institute; 2017 [cited 2017 May 9]. Available from: https://seer.cancer.gov/statfacts/html/corp.html.
 7. Zivanovic O, Carter J, Kauff ND, Barakat RR. A review of the challenges faced in the conservative 




Conservative treatment of endometrial disease
 8. Rose PG. Endometrial carcinoma. N Engl J Med 1996;335:640-9. 
PUBMED | CROSSREF
 9. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-
ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol 
Cancer 2016;26:2-30. 
PUBMED | CROSSREF
 10. Leitao MM Jr, Barakat RR. Advances in the management of endometrial carcinoma. Gynecol Oncol 
2011;120:489-92. 
PUBMED | CROSSREF
 11. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread 
patterns of endometrial cancer. a Gynecologic Oncology Group study. Cancer 1987;60:2035-41. 
PUBMED | CROSSREF
 12. Bouwman F, Smits A, Lopes A, Das N, Pollard A, Massuger L, et al. The impact of BMI on surgical 
complications and outcomes in endometrial cancer surgery--an institutional study and systematic review 
of the literature. Gynecol Oncol 2015;139:369-76. 
PUBMED | CROSSREF
 13. Suidan RS, He W, Sun CC, Zhao H, Fleming ND, Ramirez PT, et al. Impact of body mass index and 
operative approach on surgical morbidity and costs in women with endometrial carcinoma and 
hyperplasia. Gynecol Oncol 2017;145:55-60. 
PUBMED | CROSSREF
 14. Corzo C, Santillan NB, Westin SN, Ramirez PT. Updates on conservative management of endometrial 
cancer. J Minim Invasive Gynecol 2018;25:308-13. 
PUBMED | CROSSREF
 15. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-
ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol 
2016;27:16-41. 
PUBMED | CROSSREF
 16. Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P. Role of exogenous and endogenous hormones in 
endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci 2001;943:296-315. 
PUBMED | CROSSREF
 17. Steiner GJ, Kistner RW, Craig JM. Histological effects of progestins on hyperplasia and carcinoma in situ 
of the endometrium--further observations. Metabolism 1963;14 SUPPL:356-86. 
PUBMED | CROSSREF
 18. Liggins GC. Treatment of endometrial carcinoma with a progestogen. Report of a case. N Z Med J 
1963;62:235-6.
PUBMED
 19. Wentz WB. Effect of a progestational agent on endometrial hyperplasia and endometrial cancer. Obstet 
Gynecol 1964;24:370-5. 
PUBMED | CROSSREF
 20. Kistner RW. Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium. 
Cancer 1959;12:1106-22. 
PUBMED | CROSSREF
 21. Abu Hashim H, Ghayaty E, El Rakhawy M. Levonorgestrel-releasing intrauterine system vs oral progestins 
for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. Am 
J Obstet Gynecol 2015;213:469-78. 
PUBMED | CROSSREF
 22. Baker J, Obermair A, Gebski V, Janda M. Efficacy of oral or intrauterine device-delivered progestin in 
patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-
analysis and systematic review of the literature. Gynecol Oncol 2012;125:263-70. 
PUBMED | CROSSREF
 23. Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK. LNG-IUS versus oral progestogen treatment for 
endometrial hyperplasia: a long-term comparative cohort study. Hum Reprod 2013;28:2966-71. 
PUBMED | CROSSREF
 24. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early 
endometrial cancer. Am J Obstet Gynecol 2002;186:651-7. 
PUBMED | CROSSREF
 25. Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A, Schmeler KM, et al. Treatment of low-
risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine 
device. Obstet Gynecol 2018;131:109-16.
PUBMED
8/9https://ejgo.org https://doi.org/10.3802/jgo.2019.30.e57
Conservative treatment of endometrial disease
 26. Marsden DE, Hacker NF. Optimal management of endometrial hyperplasia. Best Pract Res Clin Obstet 
Gynaecol 2001;15:393-405. 
PUBMED | CROSSREF
 27. Mansour D. The benefits and risks of using a levonorgestrel-releasing intrauterine system for 
contraception. Contraception 2012;85:224-34. 
PUBMED | CROSSREF
 28. Costescu DJ. Levonorgestrel-releasing intrauterine systems for long-acting contraception: current 
perspectives, safety, and patient counseling. Int J Womens Health 2016;8:589-98. 
PUBMED | CROSSREF
 29. Takeshima N, Hirai Y, Yano K, Tanaka N, Yamauchi K, Hasumi K. Ovarian metastasis in endometrial 
carcinoma. Gynecol Oncol 1998;70:183-7. 
PUBMED | CROSSREF
 30. Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, et al. Conservative therapy for 
adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central 
pathologic review and treatment outcome. Cancer Lett 2001;167:39-48. 
PUBMED | CROSSREF
9/9https://ejgo.org https://doi.org/10.3802/jgo.2019.30.e57
Conservative treatment of endometrial disease
